Bionano Genomics Inc. (BNGO) Reached A New High 2 times During The Past Five Days


As of Wednesday close, Bionano Genomics Inc.’s (NASDAQ:BNGO) stock was up $0.03, moving up 1.35 percent to $2.25. The average number of shares traded per day over the past five days has been 4,750,200 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.44 fall in that time frame. In the last twenty days, the average volume was 7,869,570, while in the previous 50 days, it was 6,966,968.

Since last month, BNGO stock retreated -3.85%. Shares of the company fell to $1.98 on 10/24/22, the lowest level in the past month. A 52-week high of $4.41 was reached on 08/11/22 after having rallying from a 52-week low of $1.16. Since the beginning of this year, BNGO’s stock price has dropped by -24.75% or -$0.74, and marked a new high 2 times. However, the stock has declined by -48.92% since its 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


BNGO stock investors should be aware that Bionano Genomics Inc. (BNGO) stock had its last reported insider trading activity 102 days ago on Aug 15. Linney Yvonne, the Director of the company, disposed of 20,000 shares for $3.62 on Aug 15. It resulted in a $72,402 divestment by the insider. BARKER DAVID L added 10,000 shares at an average price of $1.60 on May 16. The insider now owns 13,894 shares following the transaction. On Nov 29, President and CEO Holmlin R. Erik bought 5,025 shares at $3.99 apiece. The transaction was valued at $20,037.

Valuation Metrics

The stock’s beta is 2.26. Besides these, the trailing price-to-sales (P/S) ratio of 26.73, the price-to-book (PB) ratio of 2.32.

Financial Health

In the three months ended June 29, Bionano Genomics Inc.’s quick ratio stood at 5.80, while its current ratio was 6.50, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.01, and the total debt-to-equity ratio was 0.01. On the profitability front, the trailing twelve-month gross margin is 16.90% percent. Based on annual data, BNGO earned $3.87 million in gross profit and brought in $17.98 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -21.00%. Return on equity (ROE) for the past 12 months was -38.50%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. BNGO’s revenue rose 35.46% to $6.67 million during the quarter, while net income inched up to $7.22 million. While analysts expected Bionano Genomics Inc. to report -$0.09 quarterly earnings, the actual figure was -$0.11 per share, beating the consensus estimate by -22.20%. During the quarter, the company generated -$29.57 million in EBITDA. The liabilities of Bionano Genomics Inc. were 41.96 million at the end of its most recent quarter ended June 29, and its total debt was $10.76 million. The value of shareholders’ equity is $296.93 million.

Technical Picture

This quick technical analysis looks at Bionano Genomics Inc.’s (BNGO) price momentum. With a historical volatility rate of 108.05%, the RSI 9-day stood at 42.47% on 23 November.

With respect to its five-day moving average, the current Bionano Genomics Inc. price is down by -16.36% percent or -$0.44. At present, BNGO shares trade -11.42% below its 20-day simple moving average and +48.03% percent above its 100-day simple moving average. However, the stock is currently trading approximately -4.26% below its SMA50 and +0.90% above its SMA200.

Stochastic coefficient K was 11.93% and Stochastic coefficient D was 21.78%, while ATR was 0.21. Given the Stochastic reading of 13.64% for the 14-day period, the RSI (14) reading has been calculated as 46.79%. As of today, the MACD Oscillator reading stands at -0.29, while the 14-day reading stands at -0.20.

Analyst Ratings

Bionano Genomics Inc. (BNGO) has been rated Buy by analysts. According to 0 brokerage firms, BNGO is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Bionano Genomics Inc. stock as buy, with 3 recommending it as overweight.

With a median target price of $8.00, the current consensus forecast for the stock is $6.00 – $12.00. Based on these forecasts, analysts predict Bionano Genomics Inc. (BNGO) will achieve an average price target of $8.67.


Please enter your comment!
Please enter your name here